Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Antioxidants (Basel) ; 12(9)2023 Sep 07.
Article in English | MEDLINE | ID: mdl-37760038

ABSTRACT

The NRF2 transcription factor is a master regulator of the cellular oxidant/electrophile response and a drug target for the prevention/treatment of chronic diseases. A major mechanism of NRF2 activation is its escape from rapid degradation, and newly synthesized NRF2 induces cytoprotective protein expression through its cognate antioxidant response elements (AREs). However, oxidative stress can also inhibit global protein translation, thereby potentially inhibiting NRF2 protein accumulation. H2O2 has been shown to be a relatively weak inducer of NRF2 in comparison with electrophiles. In the current study, we evaluated whether levels of H2O2 that activate the NRF2/ARE pathway inhibit NRF2 protein synthesis in HaCaT keratinocytes. A weak maximum induction was observed for H2O2 in comparison with electrophiles, both for NRF2 protein accumulation and ARE reporter activation (~10-fold compared to ≥100-fold activation). At similar H2O2 concentrations, both NRF2 protein synthesis and global protein synthesis were inhibited. The manganese porphyrin antioxidant MnTMPyP rescued both global protein synthesis and NRF2 protein synthesis from H2O2 inhibition and increased ARE reporter activation. Similar results were observed for the diphenol di-tert-butylhydroquinone (dtBHQ). In conclusion, induction of the NRF2/ARE pathway by H2O2 and dtBHQ-derived oxidative species can be limited by inhibition of NRF2 protein synthesis, likely by arrest of global protein synthesis.

2.
Chembiochem ; 23(8): e202100521, 2022 04 20.
Article in English | MEDLINE | ID: mdl-35199442

ABSTRACT

Current immunotherapeutics often work by directing components of the immune system to recognize biomarkers on the surface of cancer cells to generate an immune response. However, variable changes in biomarker distribution and expression can result in inconsistent patient response. The development of a more universal tumor-homing strategy has the potential to improve selectivity and extend therapy to cancers with decreased expression or absence of specific biomarkers. Here, we designed a bifunctional agent that exploits the inherent acidic microenvironment of most solid tumors to selectively graft the surface of cancer cells with a formyl peptide receptor ligand (FPRL). Our approach is based on the pH(Low) insertion peptide (pHLIP), a unique peptide that selectively targets tumors in vivo by anchoring to cancer cells in a pH-dependent manner. We establish that selectively remodeling cancer cells with a pHLIP-based FPRL activates formyl peptide receptors on recruited immune cells, potentially initiating an immune response towards tumors.


Subject(s)
Neoplasms , Receptors, Formyl Peptide , Cell Line, Tumor , Chemotactic Factors , Humans , Ligands , Neoplasms/drug therapy , Peptides/metabolism , Peptides/pharmacology , Receptors, Formyl Peptide/metabolism
3.
J Med Chem ; 63(7): 3713-3722, 2020 04 09.
Article in English | MEDLINE | ID: mdl-32196345

ABSTRACT

A growing class of immunotherapeutics work by redirecting components of the immune system to recognize markers on the surface of cancer cells. However, such modalities will remain confined to a relatively small subgroup of patients because of the lack of universal targetable tumor biomarkers among all patients. Here, we designed a unique class of agents that exploit the inherent acidity of solid tumors to selectively graft cancer cells with immuno-engager epitopes. Our targeting approach is based on pHLIP, a unique peptide that selectively targets tumors in vivo by anchoring to cancer cell surfaces in a pH-dependent manner. We established that pHLIP-antigen conjugates trigger the recruitment of antibodies to the surface of cancer cells and induce cytotoxicity by peripheral blood mononuclear and engineered NK cells. These results indicate that these agents have the potential to be applicable to treating a wide range of solid tumors and to circumvent problems associated with narrow windows of selectivity.


Subject(s)
Epitopes/pharmacology , Immunologic Factors/pharmacology , Membrane Proteins/pharmacology , 2,4-Dinitrophenol/chemistry , 2,4-Dinitrophenol/immunology , 2,4-Dinitrophenol/pharmacology , Amino Acid Sequence , Animals , Antibodies, Monoclonal/immunology , Cell Line, Tumor , Epitopes/chemistry , Epitopes/immunology , Fluorescein-5-isothiocyanate/chemistry , Fluorescein-5-isothiocyanate/metabolism , Fluorescein-5-isothiocyanate/pharmacology , Humans , Hydrogen-Ion Concentration , Immunologic Factors/chemistry , Immunologic Factors/metabolism , Immunotherapy/methods , Killer Cells, Natural/drug effects , Membrane Proteins/chemistry , Membrane Proteins/metabolism , Mice , Neoplasms/metabolism , Neoplasms/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...